Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Budesonide Market Research Report 2026

Global Budesonide Market Research Report 2026

Industry: Pharma & Healthcare

Published Date: 2026-07-08

Pages: 155 Pages

Report ld: 5535421

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Budesonide Market Size(US$)

CAGR 2026-2032

3.2%

Market Size,2032

USD 11,245

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 9,309 million

Market Forecast in 2032(Value)

US$ 11,245 million

CAGR

3.2%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Budesonide market was valued at US$ 8994 million in 2025 and is anticipated to reach US$ 11245 million by 2032, at a CAGR of 3.2% from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Budesonide competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

In 2025, global budesonide production reached approximately 600 tons, the average price is 15000 usd/kg. Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product types: Injectable Suspension, inhaler and Inhalation Powder.

Market Concentration and Major Players:

Internationally, the budesonide market is highly concentrated, primarily in developed countries like Europe and America. Large manufacturers include AstraZeneca and Teva. Domestically, budesonide still has significant room for growth.

Manufacturing Process and Market Trends:

The budesonide manufacturing process is divided into two ends: the active pharmaceutical ingredient (API) and the inhaled formulation. The API is primarily derived from prednisolone through five steps: esterification, defatting, oxidation, alcoholysis, and condensation. The key change in recent years—replacing the highly toxic osmium tetroxide with potassium permanganate—is cost reduction and harm mitigation. The diastereomer ratio is controlled by ketalization conditions. The core of the formulation lies not in synthesis but in micronization and suspension stabilization. The API undergoes air jet milling to control the particle size to approximately 2 micrometers to match lung deposition. The suspension is then homogenized using microfluidics and coated with phospholipids to enhance physical stability. The inhaled powder formulation requires coupling with a lactose carrier and a metering device. The aerosol formulation has completed the global transition from CFCs to HFA propellants.

In the global market, the patent for AstraZeneca's original Pulmicort expired in 2019, and generic inhalers followed suit in China and India. The demand for chronic diseases such as asthma and COPD constitutes the basic market. Colon-targeted sustained-release formulations have expanded their indications to inflammatory bowel disease, becoming a second growth curve. North America and Europe maintain their main markets due to their medical systems and payment systems. In the Asia-Pacific region, the replacement of generic drugs is accelerating due to centralized procurement and local consistency evaluation. The overall barriers are still in the registration of drug-device integrated inhalation devices and the control of micronization processes. The raw material segment has become more bulky.

This report delivers a comprehensive overview of the global Budesonide market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Budesonide. The Budesonide market size, estimates, and forecasts are provided in terms of sales volume (Tons) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Budesonide market comprehensively. Regional market sizes by Dosage Form, by Application, by Prescription, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Budesonide manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Dosage Form, by Application, and by region.

MARKET SEGMENTATION

By Company

AstraZeneca (UK)
Teva (Israel)
Viatris (USA)
Cipla (India)
Cosmo Pharmaceuticals (Ireland)
Bausch Health (Canada)
Chiesi Farmaceutici (Italy)
Orion Corporation (Finland)
Axplora (France)
Industriale Chimica (Italy)
Aarti Pharmalabs (India)
Sun Pharma (India)
Vamsi Labs (India)
Lupin (India)
Nephron (USA)
Takeda (Japan)
Calliditas (Sweden)
Dr. Falk Pharma (German)
Padagis (USA)
Lunan Better Pharma(China)
Shanghai Sine Promod(China)
Chia Tai Tianqing Pharmaceutical Group(China)
Joincare Pharmaceutical Group Industry(China)
Sichuan Purity Pharmaceutical(China)
CF PharmTech(China)
Zhejiang Furuixi Pharmaceutical(China)
Yuanda Jiuhe (Jiangxi) Pharmaceutical(China)

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Injectable Suspension
Aerosols
Inhalation Powder
Tablet and Capsule

Segment by Application

Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
Others

Segment by Category

Single-agent Budesonide
Combination Budesonide

Segment by Division

Budesonide API
Budesonide Finished Dosage Form

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Dosage Form, by Application, by Prescription, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Provides a detailed analysis of the competitive landscape for Budesonide manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.

Chapter 3: Examines Budesonide sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.

Chapter 4: Analyzes segments by Dosage Form, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.

Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.

Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.

Chapter 7: Reviews the industry value chain, including upstream and downstream segments.

Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.

Chapter 9: Summarizes the key findings and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Budesonide Market Overview

1.1 Product Definition

1.2 Budesonide by Dosage Form

1.2.1 Global Budesonide Market Value by Dosage Form: 2025 vs 2032

1.2.2 Injectable Suspension

1.2.3 Aerosols

1.2.4 Inhalation Powder

1.2.5 Tablet and Capsule

1.3 Budesonide by Prescription

1.3.1 Global Budesonide Market Value by Prescription: 2025 vs 2032

1.3.2 Single-agent Budesonide

1.3.3 Combination Budesonide

1.4 Budesonide by Specification

1.4.1 Global Budesonide Market Value by Specification: 2025 vs 2032

1.4.2 Budesonide API

1.4.3 Budesonide Finished Dosage Form

1.5 Budesonide by Application

1.5.1 Global Budesonide Market Value by Application: 2025 vs 2032

1.5.2 Respiratory Disease Treatment

1.5.3 Nose Disease Treatment

1.5.4 Inflammatory Bowel Disease Treatment

1.5.5 Others

1.6 Global Budesonide Market Size Estimates and Forecasts

1.6.1 Global Budesonide Revenue 2021–2032

1.6.2 Global Budesonide Sales 2021–2032

1.6.3 Global Budesonide Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 Budesonide Market Competition by Manufacturers

2.1 Global Budesonide Sales Market Share by Manufacturers (2021–2026)

2.2 Global Budesonide Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Budesonide Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Budesonide, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Budesonide, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Budesonide, Product Types and Applications

2.7 Global Key Manufacturers of Budesonide, Date of Entry into the Industry

2.8 Global Budesonide Market Competitive Situation and Trends

2.8.1 Global Budesonide Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Budesonide Players Market Share by Revenue

2.8.3 Global Budesonide Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Budesonide Market Scenario by Region

3.1 Global Budesonide Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Budesonide Sales by Region: 2021–2032

3.2.1 Global Budesonide Sales by Region: 2021–2026

3.2.2 Global Budesonide Sales by Region: 2027–2032

3.3 Global Budesonide Revenue by Region: 2021–2032

3.3.1 Global Budesonide Revenue by Region: 2021–2026

3.3.2 Global Budesonide Revenue by Region: 2027–2032

3.4 North America Budesonide Market Facts & Figures by Country

3.4.1 North America Budesonide Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Budesonide Sales by Country (2021–2032)

3.4.3 North America Budesonide Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Budesonide Market Facts & Figures by Country

3.5.1 Europe Budesonide Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Budesonide Sales by Country (2021–2032)

3.5.3 Europe Budesonide Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Budesonide Market Facts & Figures by Region

3.6.1 Asia Pacific Budesonide Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Budesonide Sales by Region (2021–2032)

3.6.3 Asia Pacific Budesonide Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Budesonide Market Facts & Figures by Country

3.7.1 Latin America Budesonide Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Budesonide Sales by Country (2021–2032)

3.7.3 Latin America Budesonide Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Budesonide Market Facts & Figures by Country

3.8.1 Middle East and Africa Budesonide Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Budesonide Sales by Country (2021–2032)

3.8.3 Middle East and Africa Budesonide Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Dosage Form

4.1 Global Budesonide Sales by Dosage Form (2021–2032)

4.1.1 Global Budesonide Sales by Dosage Form (2021–2026)

4.1.2 Global Budesonide Sales by Dosage Form (2027–2032)

4.1.3 Global Budesonide Sales Market Share by Dosage Form (2021–2032)

4.2 Global Budesonide Revenue by Dosage Form (2021–2032)

4.2.1 Global Budesonide Revenue by Dosage Form (2021–2026)

4.2.2 Global Budesonide Revenue by Dosage Form (2027–2032)

4.2.3 Global Budesonide Revenue Market Share by Dosage Form (2021–2032)

4.3 Global Budesonide Price by Dosage Form (2021–2032)

5 Segment by Application

5.1 Global Budesonide Sales by Application (2021–2032)

5.1.1 Global Budesonide Sales by Application (2021–2026)

5.1.2 Global Budesonide Sales by Application (2027–2032)

5.1.3 Global Budesonide Sales Market Share by Application (2021–2032)

5.2 Global Budesonide Revenue by Application (2021–2032)

5.2.1 Global Budesonide Revenue by Application (2021–2026)

5.2.2 Global Budesonide Revenue by Application (2027–2032)

5.2.3 Global Budesonide Revenue Market Share by Application (2021–2032)

5.3 Global Budesonide Price by Application (2021–2032)

6 Key Companies Profiled

6.1 AstraZeneca (UK)

6.1.1 AstraZeneca (UK) Company Information

6.1.2 AstraZeneca (UK) Description and Business Overview

6.1.3 AstraZeneca (UK) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 AstraZeneca (UK) Budesonide Product Portfolio

6.1.5 AstraZeneca (UK) Recent Developments/Updates

6.2 Teva (Israel)

6.2.1 Teva (Israel) Company Information

6.2.2 Teva (Israel) Description and Business Overview

6.2.3 Teva (Israel) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Teva (Israel) Budesonide Product Portfolio

6.2.5 Teva (Israel) Recent Developments/Updates

6.3 Viatris (USA)

6.3.1 Viatris (USA) Company Information

6.3.2 Viatris (USA) Description and Business Overview

6.3.3 Viatris (USA) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Viatris (USA) Budesonide Product Portfolio

6.3.5 Viatris (USA) Recent Developments/Updates

6.4 Cipla (India)

6.4.1 Cipla (India) Company Information

6.4.2 Cipla (India) Description and Business Overview

6.4.3 Cipla (India) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Cipla (India) Budesonide Product Portfolio

6.4.5 Cipla (India) Recent Developments/Updates

6.5 Cosmo Pharmaceuticals (Ireland)

6.5.1 Cosmo Pharmaceuticals (Ireland) Company Information

6.5.2 Cosmo Pharmaceuticals (Ireland) Description and Business Overview

6.5.3 Cosmo Pharmaceuticals (Ireland) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Cosmo Pharmaceuticals (Ireland) Budesonide Product Portfolio

6.5.5 Cosmo Pharmaceuticals (Ireland) Recent Developments/Updates

6.6 Bausch Health (Canada)

6.6.1 Bausch Health (Canada) Company Information

6.6.2 Bausch Health (Canada) Description and Business Overview

6.6.3 Bausch Health (Canada) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Bausch Health (Canada) Budesonide Product Portfolio

6.6.5 Bausch Health (Canada) Recent Developments/Updates

6.7 Chiesi Farmaceutici (Italy)

6.7.1 Chiesi Farmaceutici (Italy) Company Information

6.7.2 Chiesi Farmaceutici (Italy) Description and Business Overview

6.7.3 Chiesi Farmaceutici (Italy) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Chiesi Farmaceutici (Italy) Budesonide Product Portfolio

6.7.5 Chiesi Farmaceutici (Italy) Recent Developments/Updates

6.8 Orion Corporation (Finland)

6.8.1 Orion Corporation (Finland) Company Information

6.8.2 Orion Corporation (Finland) Description and Business Overview

6.8.3 Orion Corporation (Finland) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Orion Corporation (Finland) Budesonide Product Portfolio

6.8.5 Orion Corporation (Finland) Recent Developments/Updates

6.9 Axplora (France)

6.9.1 Axplora (France) Company Information

6.9.2 Axplora (France) Description and Business Overview

6.9.3 Axplora (France) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Axplora (France) Budesonide Product Portfolio

6.9.5 Axplora (France) Recent Developments/Updates

6.10 Industriale Chimica (Italy)

6.10.1 Industriale Chimica (Italy) Company Information

6.10.2 Industriale Chimica (Italy) Description and Business Overview

6.10.3 Industriale Chimica (Italy) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 Industriale Chimica (Italy) Budesonide Product Portfolio

6.10.5 Industriale Chimica (Italy) Recent Developments/Updates

6.11 Aarti Pharmalabs (India)

6.11.1 Aarti Pharmalabs (India) Company Information

6.11.2 Aarti Pharmalabs (India) Description and Business Overview

6.11.3 Aarti Pharmalabs (India) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.11.4 Aarti Pharmalabs (India) Budesonide Product Portfolio

6.11.5 Aarti Pharmalabs (India) Recent Developments/Updates

6.12 Sun Pharma (India)

6.12.1 Sun Pharma (India) Company Information

6.12.2 Sun Pharma (India) Description and Business Overview

6.12.3 Sun Pharma (India) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.12.4 Sun Pharma (India) Budesonide Product Portfolio

6.12.5 Sun Pharma (India) Recent Developments/Updates

6.13 Vamsi Labs (India)

6.13.1 Vamsi Labs (India) Company Information

6.13.2 Vamsi Labs (India) Description and Business Overview

6.13.3 Vamsi Labs (India) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.13.4 Vamsi Labs (India) Budesonide Product Portfolio

6.13.5 Vamsi Labs (India) Recent Developments/Updates

6.14 Lupin (India)

6.14.1 Lupin (India) Company Information

6.14.2 Lupin (India) Description and Business Overview

6.14.3 Lupin (India) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.14.4 Lupin (India) Budesonide Product Portfolio

6.14.5 Lupin (India) Recent Developments/Updates

6.15 Nephron (USA)

6.15.1 Nephron (USA) Company Information

6.15.2 Nephron (USA) Description and Business Overview

6.15.3 Nephron (USA) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.15.4 Nephron (USA) Budesonide Product Portfolio

6.15.5 Nephron (USA) Recent Developments/Updates

6.16 Takeda (Japan)

6.16.1 Takeda (Japan) Company Information

6.16.2 Takeda (Japan) Description and Business Overview

6.16.3 Takeda (Japan) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.16.4 Takeda (Japan) Budesonide Product Portfolio

6.16.5 Takeda (Japan) Recent Developments/Updates

6.17 Calliditas (Sweden)

6.17.1 Calliditas (Sweden) Company Information

6.17.2 Calliditas (Sweden) Description and Business Overview

6.17.3 Calliditas (Sweden) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.17.4 Calliditas (Sweden) Budesonide Product Portfolio

6.17.5 Calliditas (Sweden) Recent Developments/Updates

6.18 Dr. Falk Pharma (German)

6.18.1 Dr. Falk Pharma (German) Company Information

6.18.2 Dr. Falk Pharma (German) Description and Business Overview

6.18.3 Dr. Falk Pharma (German) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.18.4 Dr. Falk Pharma (German) Budesonide Product Portfolio

6.18.5 Dr. Falk Pharma (German) Recent Developments/Updates

6.19 Padagis (USA)

6.19.1 Padagis (USA) Company Information

6.19.2 Padagis (USA) Description and Business Overview

6.19.3 Padagis (USA) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.19.4 Padagis (USA) Budesonide Product Portfolio

6.19.5 Padagis (USA) Recent Developments/Updates

6.20 Lunan Better Pharma(China)

6.20.1 Lunan Better Pharma(China) Company Information

6.20.2 Lunan Better Pharma(China) Description and Business Overview

6.20.3 Lunan Better Pharma(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.20.4 Lunan Better Pharma(China) Budesonide Product Portfolio

6.20.5 Lunan Better Pharma(China) Recent Developments/Updates

6.21 Shanghai Sine Promod(China)

6.21.1 Shanghai Sine Promod(China) Company Information

6.21.2 Shanghai Sine Promod(China) Description and Business Overview

6.21.3 Shanghai Sine Promod(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.21.4 Shanghai Sine Promod(China) Budesonide Product Portfolio

6.21.5 Shanghai Sine Promod(China) Recent Developments/Updates

6.22 Chia Tai Tianqing Pharmaceutical Group(China)

6.22.1 Chia Tai Tianqing Pharmaceutical Group(China) Company Information

6.22.2 Chia Tai Tianqing Pharmaceutical Group(China) Description and Business Overview

6.22.3 Chia Tai Tianqing Pharmaceutical Group(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.22.4 Chia Tai Tianqing Pharmaceutical Group(China) Budesonide Product Portfolio

6.22.5 Chia Tai Tianqing Pharmaceutical Group(China) Recent Developments/Updates

6.23 Joincare Pharmaceutical Group Industry(China)

6.23.1 Joincare Pharmaceutical Group Industry(China) Company Information

6.23.2 Joincare Pharmaceutical Group Industry(China) Description and Business Overview

6.23.3 Joincare Pharmaceutical Group Industry(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.23.4 Joincare Pharmaceutical Group Industry(China) Budesonide Product Portfolio

6.23.5 Joincare Pharmaceutical Group Industry(China) Recent Developments/Updates

6.24 Sichuan Purity Pharmaceutical(China)

6.24.1 Sichuan Purity Pharmaceutical(China) Company Information

6.24.2 Sichuan Purity Pharmaceutical(China) Description and Business Overview

6.24.3 Sichuan Purity Pharmaceutical(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.24.4 Sichuan Purity Pharmaceutical(China) Budesonide Product Portfolio

6.24.5 Sichuan Purity Pharmaceutical(China) Recent Developments/Updates

6.25 CF PharmTech(China)

6.25.1 CF PharmTech(China) Company Information

6.25.2 CF PharmTech(China) Description and Business Overview

6.25.3 CF PharmTech(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.25.4 CF PharmTech(China) Budesonide Product Portfolio

6.25.5 CF PharmTech(China) Recent Developments/Updates

6.26 Zhejiang Furuixi Pharmaceutical(China)

6.26.1 Zhejiang Furuixi Pharmaceutical(China) Company Information

6.26.2 Zhejiang Furuixi Pharmaceutical(China) Description and Business Overview

6.26.3 Zhejiang Furuixi Pharmaceutical(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.26.4 Zhejiang Furuixi Pharmaceutical(China) Budesonide Product Portfolio

6.26.5 Zhejiang Furuixi Pharmaceutical(China) Recent Developments/Updates

6.27 Yuanda Jiuhe (Jiangxi) Pharmaceutical(China)

6.27.1 Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Company Information

6.27.2 Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Description and Business Overview

6.27.3 Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Budesonide Sales, Revenue, and Gross Margin (2021–2026)

6.27.4 Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Budesonide Product Portfolio

6.27.5 Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Budesonide Industry Chain Analysis

7.2 Budesonide Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Budesonide Production Mode & Process Analysis

7.4 Budesonide Sales and Marketing

7.4.1 Budesonide Sales Channels

7.4.2 Budesonide Distributors

7.5 Budesonide Customer Analysis

8 Budesonide Market Dynamics

8.1 Budesonide Industry Trends

8.2 Budesonide Market Drivers

8.3 Budesonide Market Challenges

8.4 Budesonide Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Budesonide Market Value by Dosage Form (US$ Million), 2025 vs 2032

Table 2. Global Budesonide Market Value by Prescription (US$ Million), 2025 vs 2032

Table 3. Global Budesonide Market Value by Specification (US$ Million), 2025 vs 2032

Table 4. Global Budesonide Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global Budesonide Market Competitive Situation by Manufacturers in 2025

Table 6. Global Budesonide Sales (Tons) of Key Manufacturers (2021–2026)

Table 7. Global Budesonide Sales Market Share by Manufacturers (2021–2026)

Table 8. Global Budesonide Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global Budesonide Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market Budesonide Average Price (US$/kg) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of Budesonide, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of Budesonide, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of Budesonide, Product Types and Applications

Table 14. Global Key Manufacturers of Budesonide, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Budesonide Companies by Tier (Tier 1, Tier 2, Tier 3), based on Budesonide Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Budesonide Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global Budesonide Sales by Region (Tons), 2021–2026

Table 20. Global Budesonide Sales Market Share by Region (2021–2026)

Table 21. Global Budesonide Sales by Region (Tons), 2027–2032

Table 22. Global Budesonide Sales Market Share by Region (2027–2032)

Table 23. Global Budesonide Revenue by Region (US$ Million), 2021–2026

Table 24. Global Budesonide Revenue Market Share by Region (2021–2026)

Table 25. Global Budesonide Revenue by Region (US$ Million), 2027–2032

Table 26. Global Budesonide Revenue Market Share by Region (2027–2032)

Table 27. North America Budesonide Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America Budesonide Sales by Country (Tons), 2021–2026

Table 29. North America Budesonide Sales by Country (Tons), 2027–2032

Table 30. North America Budesonide Revenue by Country (US$ Million), 2021–2026

Table 31. North America Budesonide Revenue by Country (US$ Million), 2027–2032

Table 32. Europe Budesonide Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe Budesonide Sales by Country (Tons), 2021–2026

Table 34. Europe Budesonide Sales by Country (Tons), 2027–2032

Table 35. Europe Budesonide Revenue by Country (US$ Million), 2021–2026

Table 36. Europe Budesonide Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific Budesonide Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific Budesonide Sales by Region (Tons), 2021–2026

Table 39. Asia Pacific Budesonide Sales by Region (Tons), 2027–2032

Table 40. Asia Pacific Budesonide Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific Budesonide Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America Budesonide Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America Budesonide Sales by Country (Tons), 2021–2026

Table 44. Latin America Budesonide Sales by Country (Tons), 2027–2032

Table 45. Latin America Budesonide Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America Budesonide Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa Budesonide Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa Budesonide Sales by Country (Tons), 2021–2026

Table 49. Middle East and Africa Budesonide Sales by Country (Tons), 2027–2032

Table 50. Middle East and Africa Budesonide Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa Budesonide Revenue by Country (US$ Million), 2027–2032

Table 52. Global Budesonide Sales (Tons) by Dosage Form (2021–2026)

Table 53. Global Budesonide Sales (Tons) by Dosage Form (2027–2032)

Table 54. Global Budesonide Sales Market Share by Dosage Form (2021–2026)

Table 55. Global Budesonide Sales Market Share by Dosage Form (2027–2032)

Table 56. Global Budesonide Revenue (US$ Million) by Dosage Form (2021–2026)

Table 57. Global Budesonide Revenue (US$ Million) by Dosage Form (2027–2032)

Table 58. Global Budesonide Revenue Market Share by Dosage Form (2021–2026)

Table 59. Global Budesonide Revenue Market Share by Dosage Form (2027–2032)

Table 60. Global Budesonide Price (US$/kg) by Dosage Form (2021–2026)

Table 61. Global Budesonide Price (US$/kg) by Dosage Form (2027–2032)

Table 62. Global Budesonide Sales (Tons) by Application (2021–2026)

Table 63. Global Budesonide Sales (Tons) by Application (2027–2032)

Table 64. Global Budesonide Sales Market Share by Application (2021–2026)

Table 65. Global Budesonide Sales Market Share by Application (2027–2032)

Table 66. Global Budesonide Revenue (US$ Million) by Application (2021–2026)

Table 67. Global Budesonide Revenue (US$ Million) by Application (2027–2032)

Table 68. Global Budesonide Revenue Market Share by Application (2021–2026)

Table 69. Global Budesonide Revenue Market Share by Application (2027–2032)

Table 70. Global Budesonide Price (US$/kg) by Application (2021–2026)

Table 71. Global Budesonide Price (US$/kg) by Application (2027–2032)

Table 72. AstraZeneca (UK) Company Information

Table 73. AstraZeneca (UK) Description and Business Overview

Table 74. AstraZeneca (UK) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 75. AstraZeneca (UK) Budesonide Product

Table 76. AstraZeneca (UK) Recent Developments/Updates

Table 77. Teva (Israel) Company Information

Table 78. Teva (Israel) Description and Business Overview

Table 79. Teva (Israel) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 80. Teva (Israel) Budesonide Product

Table 81. Teva (Israel) Recent Developments/Updates

Table 82. Viatris (USA) Company Information

Table 83. Viatris (USA) Description and Business Overview

Table 84. Viatris (USA) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 85. Viatris (USA) Budesonide Product

Table 86. Viatris (USA) Recent Developments/Updates

Table 87. Cipla (India) Company Information

Table 88. Cipla (India) Description and Business Overview

Table 89. Cipla (India) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 90. Cipla (India) Budesonide Product

Table 91. Cipla (India) Recent Developments/Updates

Table 92. Cosmo Pharmaceuticals (Ireland) Company Information

Table 93. Cosmo Pharmaceuticals (Ireland) Description and Business Overview

Table 94. Cosmo Pharmaceuticals (Ireland) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 95. Cosmo Pharmaceuticals (Ireland) Budesonide Product

Table 96. Cosmo Pharmaceuticals (Ireland) Recent Developments/Updates

Table 97. Bausch Health (Canada) Company Information

Table 98. Bausch Health (Canada) Description and Business Overview

Table 99. Bausch Health (Canada) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 100. Bausch Health (Canada) Budesonide Product

Table 101. Bausch Health (Canada) Recent Developments/Updates

Table 102. Chiesi Farmaceutici (Italy) Company Information

Table 103. Chiesi Farmaceutici (Italy) Description and Business Overview

Table 104. Chiesi Farmaceutici (Italy) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 105. Chiesi Farmaceutici (Italy) Budesonide Product

Table 106. Chiesi Farmaceutici (Italy) Recent Developments/Updates

Table 107. Orion Corporation (Finland) Company Information

Table 108. Orion Corporation (Finland) Description and Business Overview

Table 109. Orion Corporation (Finland) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 110. Orion Corporation (Finland) Budesonide Product

Table 111. Orion Corporation (Finland) Recent Developments/Updates

Table 112. Axplora (France) Company Information

Table 113. Axplora (France) Description and Business Overview

Table 114. Axplora (France) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 115. Axplora (France) Budesonide Product

Table 116. Axplora (France) Recent Developments/Updates

Table 117. Industriale Chimica (Italy) Company Information

Table 118. Industriale Chimica (Italy) Description and Business Overview

Table 119. Industriale Chimica (Italy) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 120. Industriale Chimica (Italy) Budesonide Product

Table 121. Industriale Chimica (Italy) Recent Developments/Updates

Table 122. Aarti Pharmalabs (India) Company Information

Table 123. Aarti Pharmalabs (India) Description and Business Overview

Table 124. Aarti Pharmalabs (India) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 125. Aarti Pharmalabs (India) Budesonide Product

Table 126. Aarti Pharmalabs (India) Recent Developments/Updates

Table 127. Sun Pharma (India) Company Information

Table 128. Sun Pharma (India) Description and Business Overview

Table 129. Sun Pharma (India) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 130. Sun Pharma (India) Budesonide Product

Table 131. Sun Pharma (India) Recent Developments/Updates

Table 132. Vamsi Labs (India) Company Information

Table 133. Vamsi Labs (India) Description and Business Overview

Table 134. Vamsi Labs (India) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 135. Vamsi Labs (India) Budesonide Product

Table 136. Vamsi Labs (India) Recent Developments/Updates

Table 137. Lupin (India) Company Information

Table 138. Lupin (India) Description and Business Overview

Table 139. Lupin (India) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 140. Lupin (India) Budesonide Product

Table 141. Lupin (India) Recent Developments/Updates

Table 142. Nephron (USA) Company Information

Table 143. Nephron (USA) Description and Business Overview

Table 144. Nephron (USA) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 145. Nephron (USA) Budesonide Product

Table 146. Nephron (USA) Recent Developments/Updates

Table 147. Takeda (Japan) Company Information

Table 148. Takeda (Japan) Description and Business Overview

Table 149. Takeda (Japan) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 150. Takeda (Japan) Budesonide Product

Table 151. Takeda (Japan) Recent Developments/Updates

Table 152. Calliditas (Sweden) Company Information

Table 153. Calliditas (Sweden) Description and Business Overview

Table 154. Calliditas (Sweden) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 155. Calliditas (Sweden) Budesonide Product

Table 156. Calliditas (Sweden) Recent Developments/Updates

Table 157. Dr. Falk Pharma (German) Company Information

Table 158. Dr. Falk Pharma (German) Description and Business Overview

Table 159. Dr. Falk Pharma (German) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 160. Dr. Falk Pharma (German) Budesonide Product

Table 161. Dr. Falk Pharma (German) Recent Developments/Updates

Table 162. Padagis (USA) Company Information

Table 163. Padagis (USA) Description and Business Overview

Table 164. Padagis (USA) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 165. Padagis (USA) Budesonide Product

Table 166. Padagis (USA) Recent Developments/Updates

Table 167. Lunan Better Pharma(China) Company Information

Table 168. Lunan Better Pharma(China) Description and Business Overview

Table 169. Lunan Better Pharma(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 170. Lunan Better Pharma(China) Budesonide Product

Table 171. Lunan Better Pharma(China) Recent Developments/Updates

Table 172. Shanghai Sine Promod(China) Company Information

Table 173. Shanghai Sine Promod(China) Description and Business Overview

Table 174. Shanghai Sine Promod(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 175. Shanghai Sine Promod(China) Budesonide Product

Table 176. Shanghai Sine Promod(China) Recent Developments/Updates

Table 177. Chia Tai Tianqing Pharmaceutical Group(China) Company Information

Table 178. Chia Tai Tianqing Pharmaceutical Group(China) Description and Business Overview

Table 179. Chia Tai Tianqing Pharmaceutical Group(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 180. Chia Tai Tianqing Pharmaceutical Group(China) Budesonide Product

Table 181. Chia Tai Tianqing Pharmaceutical Group(China) Recent Developments/Updates

Table 182. Joincare Pharmaceutical Group Industry(China) Company Information

Table 183. Joincare Pharmaceutical Group Industry(China) Description and Business Overview

Table 184. Joincare Pharmaceutical Group Industry(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 185. Joincare Pharmaceutical Group Industry(China) Budesonide Product

Table 186. Joincare Pharmaceutical Group Industry(China) Recent Developments/Updates

Table 187. Sichuan Purity Pharmaceutical(China) Company Information

Table 188. Sichuan Purity Pharmaceutical(China) Description and Business Overview

Table 189. Sichuan Purity Pharmaceutical(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 190. Sichuan Purity Pharmaceutical(China) Budesonide Product

Table 191. Sichuan Purity Pharmaceutical(China) Recent Developments/Updates

Table 192. CF PharmTech(China) Company Information

Table 193. CF PharmTech(China) Description and Business Overview

Table 194. CF PharmTech(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 195. CF PharmTech(China) Budesonide Product

Table 196. CF PharmTech(China) Recent Developments/Updates

Table 197. Zhejiang Furuixi Pharmaceutical(China) Company Information

Table 198. Zhejiang Furuixi Pharmaceutical(China) Description and Business Overview

Table 199. Zhejiang Furuixi Pharmaceutical(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 200. Zhejiang Furuixi Pharmaceutical(China) Budesonide Product

Table 201. Zhejiang Furuixi Pharmaceutical(China) Recent Developments/Updates

Table 202. Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Company Information

Table 203. Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Description and Business Overview

Table 204. Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Budesonide Sales (Tons), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)

Table 205. Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Budesonide Product

Table 206. Yuanda Jiuhe (Jiangxi) Pharmaceutical(China) Recent Developments/Updates

Table 207. Key Raw Materials Lists

Table 208. Raw Materials Key Suppliers Lists

Table 209. Budesonide Distributors List

Table 210. Budesonide Customers List

Table 211. Budesonide Market Trends

Table 212. Budesonide Market Drivers

Table 213. Budesonide Market Challenges

Table 214. Budesonide Market Restraints

Table 215. Research Programs/Design for This Report

Table 216. Key Data Information from Secondary Sources

Table 217. Key Data Information from Primary Sources

Table 218. Authors List of This Report

List of Figures

Figure 1. Product Picture of Budesonide

Figure 2. Global Budesonide Market Value by Dosage Form (US$ Million), 2021–2032

Figure 3. Global Budesonide Market Share by Dosage Form: 2025 & 2032

Figure 4. Injectable Suspension Product Picture

Figure 5. Aerosols Product Picture

Figure 6. Inhalation Powder Product Picture

Figure 7. Tablet and Capsule Product Picture

Figure 8. Global Budesonide Market Value by Prescription (US$ Million), 2021–2032

Figure 9. Global Budesonide Market Share by Prescription: 2025 vs 2032

Figure 10. Single-agent Budesonide Product Picture

Figure 11. Combination Budesonide Product Picture

Figure 12. Global Budesonide Market Value by Specification (US$ Million), 2021–2032

Figure 13. Global Budesonide Market Share by Specification: 2025 vs 2032

Figure 14. Budesonide API Product Picture

Figure 15. Budesonide Finished Dosage Form Product Picture

Figure 16. Global Budesonide Market Value by Application (US$ Million), 2021–2032

Figure 17. Global Budesonide Market Share by Application: 2025 & 2032

Figure 18. Respiratory Disease Treatment

Figure 19. Nose Disease Treatment

Figure 20. Inflammatory Bowel Disease Treatment

Figure 21. Others

Figure 22. Global Budesonide Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 23. Global Budesonide Market Size (US$ Million), 2021–2032

Figure 24. Global Budesonide Sales (Tons), 2021–2032

Figure 25. Global Budesonide Average Price (US$/kg), 2021–2032

Figure 26. Budesonide Report Years Considered

Figure 27. Budesonide Sales Share by Manufacturers in 2025

Figure 28. Global Budesonide Revenue Share by Manufacturers in 2025

Figure 29. Top 5 and Top 10 Global Budesonide Players: Market Share by Revenue in Budesonide in 2025

Figure 30. Budesonide Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 31. Global Budesonide Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 32. North America Budesonide Sales Market Share by Country (2021–2032)

Figure 33. North America Budesonide Revenue Market Share by Country (2021–2032)

Figure 34. U.S. Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Canada Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. Europe Budesonide Sales Market Share by Country (2021–2032)

Figure 37. Europe Budesonide Revenue Market Share by Country (2021–2032)

Figure 38. Germany Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. France Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. U.K. Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Italy Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Russia Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Asia Pacific Budesonide Sales Market Share by Region (2021–2032)

Figure 44. Asia Pacific Budesonide Revenue Market Share by Region (2021–2032)

Figure 45. China Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Japan Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. South Korea Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. India Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Australia Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Taiwan Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Indonesia Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Thailand Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Malaysia Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Philippines Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. Latin America Budesonide Sales Market Share by Country (2021–2032)

Figure 56. Latin America Budesonide Revenue Market Share by Country (2021–2032)

Figure 57. Mexico Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 58. Brazil Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 59. Argentina Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Middle East and Africa Budesonide Sales Market Share by Country (2021–2032)

Figure 61. Middle East and Africa Budesonide Revenue Market Share by Country (2021–2032)

Figure 62. Turkey Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 63. Saudi Arabia Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 64. U.A.E Budesonide Revenue Growth Rate (US$ Million), 2021–2032

Figure 65. Global Sales Market Share of Budesonide by Dosage Form (2021–2032)

Figure 66. Global Revenue Market Share of Budesonide by Dosage Form (2021–2032)

Figure 67. Global Budesonide Price (US$/kg) by Dosage Form (2021–2032)

Figure 68. Global Sales Market Share of Budesonide by Application (2021–2032)

Figure 69. Global Revenue Market Share of Budesonide by Application (2021–2032)

Figure 70. Global Budesonide Price (US$/kg) by Application (2021–2032)

Figure 71. Budesonide Value Chain

Figure 72. Channels of Distribution (Direct Vs Distribution)

Figure 73. Bottom-up and Top-down Approaches for This Report

Figure 74. Data Triangulation

Figure 75. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Budesonide market? zhanKai

The top companies in the global Budesonide market are AstraZeneca (UK)、Teva (Israel)、Viatris (USA).

What is the annual compound growth rate of the global Budesonide market size from 2026 to 2032? shouQi

What was the global market size of Budesonide in 2026? shouQi

What was the global market size of Budesonide in 2032? shouQi

Which region is expected to have the highest market share? shouQi

Related Reports

Global Budesonide Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Budesonide market is projected to grow from US$ 8994 million in 2025 to US$ 11245 million by 2032, at a CAGR of 3.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-07-08
Pages: 205
USD 4900.00
(Single User License)
Global Budesonide Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Budesonide market size was US$ 8994 million in 2025 and is forecast to reach a readjusted size of US$ 11245 million by 2032 with a CAGR of 3.2% during the forecast period 2026-2032.
Published Date: 2026-07-08
Pages: 170
USD 4250.00
(Single User License)
Budesonide- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Budesonide was estimated to be worth US$ 8994 million in 2025 and is projected to reach US$ 11245 million, growing at a CAGR of 3.2% from 2026 to 2032.
Published Date: 2026-07-08
Pages: 167
USD 3950.00
(Single User License)
Global Budesonide Market Report, History and Forecast 2021-2032
The global market for Budesonide was valued at US$ 8984 million in the year 2023 and is projected to reach a revised size of US$ 11165 million by 2030, growing at a CAGR of 3.2% during the forecast period 2024-2030.
Published Date: 2026-06-17
Pages: 133
USD 3350.00
(Single User License)
Global Budesonide Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Budesonide market is projected to grow from US$ 8732 million in 2024 to US$ 10850 million by 2031, at a CAGR of 3.2% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 153
USD 4900.00
(Single User License)
Global Budesonide Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Budesonide was estimated to be worth US$ 8732 million and is forecast to reach approximately US$ 10850 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 144
USD 5900.00
(Single User License)
Global Budesonide Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Budesonide market size was US$ 8732 million in 2024 and is forecast to a readjusted size of US$ 10850 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 99
USD 4250.00
(Single User License)
Budesonide- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Budesonide was estimated to be worth US$ 8732 million in 2024 and is forecast to a readjusted size of US$ 10850 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 126
USD 3950.00
(Single User License)
Global Budesonide Market Research Report 2025
The global market for Budesonide was valued at US$ 8732 million in the year 2024 and is projected to reach a revised size of US$ 10850 million by 2031, growing at a CAGR of 3.2% during the forecast period.
Published Date: 2025-01-16
Pages: 91
USD 2900.00
(Single User License)
Global Budesonide Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product types: Injectable Suspension, inhaler and Inhalation Powder.
Published Date: 2024-04-17
Pages: 156
USD 5600.00
(Single User License)

Global Budesonide Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Budesonide market is projected to grow from US$ 8994 million in 2025 to US$ 11245 million by 2032, at a CAGR of 3.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-07-08
Pages: 205
USD 4900.00 (Single User License)
Global Budesonide Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Budesonide market size was US$ 8994 million in 2025 and is forecast to reach a readjusted size of US$ 11245 million by 2032 with a CAGR of 3.2% during the forecast period 2026-2032.
Published: 2026-07-08
Pages: 170
USD 4250.00 (Single User License)
Budesonide- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Budesonide was estimated to be worth US$ 8994 million in 2025 and is projected to reach US$ 11245 million, growing at a CAGR of 3.2% from 2026 to 2032.
Published: 2026-07-08
Pages: 167
USD 3950.00 (Single User License)
Global Budesonide Market Report, History and Forecast 2021-2032
The global market for Budesonide was valued at US$ 8984 million in the year 2023 and is projected to reach a revised size of US$ 11165 million by 2030, growing at a CAGR of 3.2% during the forecast period 2024-2030.
Published: 2026-06-17
Pages: 133
USD 3350.00 (Single User License)
Global Budesonide Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Budesonide market is projected to grow from US$ 8732 million in 2024 to US$ 10850 million by 2031, at a CAGR of 3.2% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 153
USD 4900.00 (Single User License)
Global Budesonide Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Budesonide was estimated to be worth US$ 8732 million and is forecast to reach approximately US$ 10850 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 144
USD 5900.00 (Single User License)
Global Budesonide Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Budesonide market size was US$ 8732 million in 2024 and is forecast to a readjusted size of US$ 10850 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 99
USD 4250.00 (Single User License)
Budesonide- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Budesonide was estimated to be worth US$ 8732 million in 2024 and is forecast to a readjusted size of US$ 10850 million by 2031 with a CAGR of 3.2% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 126
USD 3950.00 (Single User License)
Global Budesonide Market Research Report 2025
The global market for Budesonide was valued at US$ 8732 million in the year 2024 and is projected to reach a revised size of US$ 10850 million by 2031, growing at a CAGR of 3.2% during the forecast period.
Published: 2025-01-16
Pages: 91
USD 2900.00 (Single User License)
Global Budesonide Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product types: Injectable Suspension, inhaler and Inhalation Powder.
Published: 2024-04-17
Pages: 156
USD 5600.00 (Single User License)